> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Court Denies FDA Move Against California Stem Cell Clinics
- URL: https://www.fdaweb.com/court-denies-fda-move-against-california-stem-cell-clinics/
- Published: 2020-01-29T12:00:00.000Z
- Updated: 2026-09-14T16:00:26.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5145959

A California federal judge has [denied](https://assets.documentcloud.org/documents/6682558/Stem-Cell-Berman-Ruling.pdf?ref=fdaweb.com) an FDA request for summary judgment in its case against a network of clinics that the government says is offering customers unauthorized stem cell treatments. FDA had wanted to shut down activities at the California Stem Cell Treatment Center and the Cell Surgical Network, saying the clinics were using unapproved drugs to treat patients suffering from conditions such as cancer, arthritis, multiple sclerosis, diabetes, Lou Gehrig’s disease, and Parkinson’s disease. The clinics have said their treatments involve substances that are exempt from FDA oversight, in part because they come from their patients’ bodies.

The *Los Angeles Times* [reports](https://www.latimes.com/business/story/2020-01-28/judge-fda-stem-cell-clinics?ref=fdaweb.com) that although FDA won summary judgment in a Florida federal court against U.S. Stem Cell Clinic, the California judge may have been influenced by a Supreme Court decision that came after the Florida ruling in which the high court narrowed the circumstances in which courts must defer to a federal agency’s interpretation of its own rules. Judge **Jesus Bernal** cited the Supreme Court decision in finding that FDA’s interpretation of its rules defining stem cell preparations as illegal drugs “is not entitled to deference,” the newspaper says. Florida federal judge **Ursula Ungaro** had ruled that the FDA interpretation must be given deference.

FDA declined to comment to the *Times* on the ruling because the case is still “pending litigation.” Through the Justice Department, the agency had said in the California case that the purportedly stem-cell-rich solution used by the clinics required FDA approval. “There have been no adequate and well-controlled studies performed on the … products demonstrating that they are safe or effective for any indication,” it said.

The *Times* says that providers targeted by FDA typically remove fat tissue from patients by liposuction, treat the fat to extract or concentrate stem cells in the tissue, and inject the concentrate back into the patients for supposedly therapeutic purposes. FDA has not approved any treatments using fat cells, it says.

The judge held that given the competing claims from the government and clinics about the procedure, “there is a triable issue of fact and summary judgment is not appropriate.”